Tezepelumab

Tezepelumab is indicated for the add-on maintenance treatment of people aged twelve years and older with severe asthma. ==Side effects==

The most common side effects include arthralgia (joint pain) and pharyngitis (sore throat). ==Pharmacodynamics==

Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation. Structural studies by X-ray crystallography showed that tezepelumab competes against a critical part of the TSLPR binding site on TSLP. == History ==

In 2020, tezepelumab demonstrated efficacy compared to placebo for patients with severe, uncontrolled asthma in phase III trials. Two main studies including over 1,500 adults and adolescents with inadequately controlled asthma showed that tezepelumab was effective in reducing the number of severe asthma flare‑ups, as evaluated in two clinical trials of participants with severe asthma. All participants were taking their usual treatment for asthma and participants received new treatment with either tezepelumab or placebo. Neither the participants nor the investigators knew which treatment was given. The benefit of tezepelumab was assessed by measuring the frequency of asthma attacks (exacerbations) at the end of both 52 week trials in comparison to placebo. It was also studied for the treatment of chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and eosinophilic esophagitis (EoE). == Society and culture ==

Legal status In December 2021, the US Food and Drug Administration (FDA) approved tezepelumab based on evidence from two clinical trials (NAVIGATOR and PATHWAY) of 1334 participants with severe asthma. Tezepelumab was approved for medical use in the European Union in September 2022. ==See also==